Premium
The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials
Author(s) -
NEWLING D.W.W.
Publication year - 1997
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1997.tb00805.x
Subject(s) - medicine , prostate cancer , intensive care medicine , disease , randomized controlled trial , clinical trial , cancer , stage (stratigraphy) , prostate , palliative therapy , oncology , paleontology , biology
Summary The palliative therapy of advanced prostate cancer still remains a perplexing problem. If advanced prostate cancer is defined either as a primary advanced‐stage tumour (T3, T4, N0‐N1), or a rising PSA level after primary and hopefully curative therapy, or the traditional patient presenting with small‐ or large‐volume metastases with or without symptoms, then some 60% of all patients have advanced disease when first seen. There is still a need for the continuation of large prospective, randomized studies in all stages of this common illness, to define the role of the different therapeutic options at our disposal. The urological and urooncological worlds must be patient and not jump to too many early conclusions over the benefit of the various therapies until a statistical advantage for both individual and combined therapeutic options has been shown.